TD Cowen Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals Analyst Ratings
Optimistic Long-Term Outlook for ACADIA Pharmaceuticals' Daybue Drives Buy Rating
ACADIA Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)
Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Integer Holdings (ITGR) and ACADIA Pharmaceuticals (ACAD)
Neutral Outlook on ACADIA Pharmaceuticals Amidst Revenue Miss and Revised Penetration Forecasts
Buy Rating for ACADIA Pharmaceuticals Based on Promising Drug Prospects and Financial Stability
ACADIA Pharmaceuticals Analyst Ratings
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $30
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)
Maintaining Buy Rating on ACADIA Pharmaceuticals Amidst Daybue's Long-Term Growth Prospects
RBC Capital Remains a Buy on ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals Analyst Ratings
ACADIA Pharmaceuticals: Strong Sales and Promising Pipeline Justify Buy Rating
Analysts Offer Insights on Healthcare Companies: Andlauer Healthcare Group (OtherANDHF), ACADIA Pharmaceuticals (ACAD) and Chemomab Therapeutics (CMMB)
ACADIA Pharmaceuticals Analyst Ratings
ACADIA Pharmaceuticals Analyst Ratings
ACADIA Pharmaceuticals Analyst Ratings